Quarterly report pursuant to Section 13 or 15(d)

NOTE 6. STOCK OPTIONS AND SUBSCRIPTIONS PAYABLE

v3.5.0.2
NOTE 6. STOCK OPTIONS AND SUBSCRIPTIONS PAYABLE
6 Months Ended
Jun. 30, 2016
Notes to Financial Statements  
NOTE 6. STOCK OPTIONS AND SUBSCRIPTIONS PAYABLE

The Company accounts for employee and non-employee stock options under ASC 718 and ASC 505, whereby option costs are recorded based on the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. Unless otherwise provided for, the Company covers option exercises by issuing new shares.

 

The Company's stock option activity is described below.

 

Non-employee stock options

 

At the beginning of 2012, the Company had 22,500 options outstanding for shares in Transbiotec – CA. The fair value of the option grants was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions: risk free interest rate of 2.67%, dividend yield of 0%, expected life of five years, volatility of 100%. During the year ended December 31, 2012 no options were exercised or expired, leaving a December 31, 2012 outstanding balance of 22,500 non-employee stock options, exercisable at prices from $0.10 - $0.15 per share with the option terms expiring from January 2012 through January 2015. All of these options are for the stock of TransBiotec - CA. During the year ended December 31, 2014, 20,000 options were exercised, leaving a December 31, 2014 outstanding balance of 2,500 non-employee stock options, exercisable at $0.10 per share with the option terms expiring in January 2015. During the year ended December 31, 2015, no options were exercised as all outstanding options expired in January 2015 leaving no outstanding balance of non-employee stock options in the stock of Transbiotec-CA at December 31, 2015. During the six months ended June 30, 2016, no options were exercised as all outstanding options expired in January 2015 leaving no outstanding balance of non-employee stock options in the stock of Transbiotec-CA at June 30, 2016

 

During 2012 the Company granted 29,678 stock options for shares in Transbiotec - DE. The fair value of the option grants was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions: risk free interest rate of 0.8%, dividend yield of 0%, expected life of five years, volatility of 189%. No options were exercised or expired, leaving a December 31, 2012 outstanding balance of 29,678 options for Transbiotec – DE. The Company incurred and recorded compensation expense under these stock option grants of $4,042 in 2012, vested immediately.

 

During 2013 the Company granted 5,321,735 stock options for shares in Transbiotec - DE. The fair value of the option grants was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions: risk free interest rates between 7% - 14%, dividend yield of 0%, expected life of five years, volatility between 179% - 186%. No options were exercised or expired, leaving a December 31, 2013 outstanding balance of 5,351,413 options for Transbiotec – DE. The Company incurred and recorded compensation expense under these stock option grants of $145,997 in 2013, vested immediately.

 

During 2014 the Company granted 8,403,633 stock options for shares in Transbiotec - DE. The fair value of the option grants was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions: risk free interest rates between 1.55% - 1.77%, dividend yield of 0%, expected life of five years, volatility between 147% - 178%. No options were exercised or expired, leaving a December 31, 2014 outstanding balance of 13,755,046 options for Transbiotec – DE. The Company incurred and recorded compensation expense under these stock option grants of $69,886 in 2014, vested immediately.

 

During the year ended December 31, 2015, the Company granted 16,282,995 stock options for shares in Transbiotec - DE. The fair value of the option grants was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions: risk free interest rate between 1.37% - 1.68%, dividend yield of 0%, expected life of five years, a volatility range of 172% - 174%. No options were exercised or expired, leaving a December 31, 2015 outstanding balance of 30,038,041 options for Transbiotec – DE. The Company incurred and recorded compensation expense under these stock option grants of $27,731 during the year ended December 31, 2015, vested immediately.

 

During the six months ended June 30, 2016, the Company granted 2,812,500 stock options for shares in Transbiotec - DE. The fair value of the option grants was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions: risk free interest rate of 1.30%, dividend yield of 0%, expected life of five years, a volatility rate of 164%. No options were exercised or expired, leaving a June 30, 2016 outstanding balance of 32,850,541 options for Transbiotec – DE. The Company incurred and recorded compensation expense under these stock option grants of $10,523 during the six months ended June 30, 2016, vested immediately.

 

A summary of stock option activity for California is as follows:

 

   

Number of

Shares

   

Weighted Average

Exercise Price

 
             
Outstanding at December 31, 2015     -     $ -  
                 
Granted     -       -  
Exercised     -       -  
Forfeited     -       -  
Outstanding at June 30, 2016     -     $ -  

 

A summary of stock option activity for Delaware is as follows:

 

   

Number of

Shares

   

Weighted Average

Exercise Price

 
             
Outstanding at December 31, 2015     30,038,041     $ .0143  
                 
Granted     2,812,500       .0040  
Exercised     -       -  
Forfeited     -       -  
Outstanding at June 30, 2016     32,850,541     $ .0134  

 

Following is a summary of the status of options for Delaware outstanding at March 31, 2016:

 

Exercise

Price

   

Number

of Shares

   

Remaining

Contractual

Life

 

Weighted

Average

Exercise

Price

   

Exercised at

March 31,
2016

 
                         
$ 0.0900       29,678     2 years     0.0900       -  
$ 0.1700       83,333     3 years     0.1700       -  
$ 0.1700       27,778     3 years     0.1700       -  
$ 0.1700       362,624     3 years     0.1700       -  
$ 0.1300       80,914     3 years     0.1300       -  
$ 0.1300       429,086     3 years     0.1300       -  
$ 0.0600       38,000     3 years     0.0600       -  
$ 0.0400       250,000     3 years     0.0400       -  
$ 0.0400       1,625,000     3 years     0.0400       -  
$ 0.0500       400,000     3 years     0.0500       -  
$ 0.0400       75,000     3 years     0.0400       -  
$ 0.0400       300,000     3 years     0.0400       -  
$ 0.0200       300,000     3 years     0.0200       -  
$ 0.0200       1,200,000     3 years     0.0200       -  
$ 0.0400       150,000     3 years     0.0400       -  
$ 0.0125       1,200,000     4 years     0.0125          
$ 0.0150       50,137     4 years     0.0150       -  
$ 0.0150       140,000     4 years     0.0150       -  
$ 0.0190       31,256     4 years     0.0190       -  
$ 0.0161       167,702     4 years     0.0161       -  
$ 0.0147       204,082     4 years     0.0147       -  
$ 0.0200       75,000     4 years     0.0200       -  
$ 0.0198       75,758     4 years     0.0198       -  
$ 0.0213       165,915     4 years     0.0213       -  
$ 0.0195       133,262     4 years     0.0195       -  
$ 0.0188       79,787     4 years     0.0188       -  
$ 0.0140       229,714     4 years     0.0140       -  
$ 0.0190       50,000     4 years     0.0190       -  
$ 0.0127       42,283     4 years     0.0127       -  
$ 0.0090       213,833     4 years     0.0090       -  
$ 0.0074       48,649     4 years     0.0074       -  
$ 0.0060       375,000     4 years     0.0060       -  
$ 0.0098       612,245     4 years     0.0098       -  
$ 0.0098       61,224     4 years     0.0098       -  
$ 0.2500       25,000     4 years     0.2500       -  
$ 0.0680       450,000     4 years     0.0680       -  
$ 0.0072       123,828     4 years     0.0072       -  
$ 0.0056       375,000     4 years     0.0056       -  
$ 0.0070       250,000     4 years     0.0070       -  
$ 0.0070       373,714     4 years     0.0070       -  
$ 0.0041       850,244     4 years     0.0041       -  
$ 0.0045       2,000,000     4 years     0.0045       -  
$ 0.0024       150,000     5 years     0.0024       -  
$ 0.0010       7,625,544     5 years     0.0010       -  
$ 0.0024       1,770,000     5 years     0.0024       -  
$ 0.0023       400,782     5 years     0.0023       -  
$ 0.0012       275,000     5 years     0.0012       -  
$ 0.0017       1,764,706     5 years     0.0017       -  
$ 0.0018       2,463,333     5 years     0.0018       -  
$ 0.0021       285,714     5 years     0.0021       -  
$ 0.0018       333,333     5 years     0.0018       -  
$ 0.0018       1,083,333     5 years     0.0018       -  
$ 0.0018       131,250     5 years     0.0018       -  
$ 0.0040       2,250,000     5 years     0.0040       -  
$ 0.0040       562,500     5 years     0.0040       -  
Total       32,850,541           0.0134          

  

Employee stock options

 

The parent company had no outstanding employee stock options.

 

Stock subscriptions received

 

At June 30, 2016 and December 31, 2015, the Company converted certain accounts payable into common shares which amounts to $31,897 for 1,319,229 common shares to be issued, and $55,868 for 6,049,578 common shares to be issued, respectively.

 

At June 30, 2016 and December 31, 2015, the Company converted certain notes payable into preferred shares which amounts to $14 for 1,388,575 preferred shares to be issued.